Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors - PubMed (original) (raw)

Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors

Amy Moreno et al. Endocr Relat Cancer. 2008 Mar.

Abstract

The mammalian target of rapamycin (mTOR) signaling pathway has emerged as a promising target for cancer therapy. Rapamycin inhibits mTOR activity but induces upstream signaling, leading to Akt activation, potentially limiting antitumor activity. Octreotide, a somatostatin analog, decreases phosphatidylinositol-3-kinase/Akt signaling in some models, and thus theoretically may enhance rapamycin's antitumor activity. The aim of this study was to determine the antitumor activity of rapamycin and octreotide as single agents and in combination in neuroendocrine tumors. In carcinoid cell lines BON-1 and NCI-H727, cell proliferation was significantly inhibited by rapamycin in vitro, although rapamycin treatment did lead to Akt phosphorylation. Octreotide had limited antiproliferative effects alone, and did not demonstrate synergistic or additive interactions with rapamycin. Furthermore, octreotide did not overcome rapamycin-induced Akt phosphorylation. In vivo, rapamycin alone caused significant tumor suppression. Octreotide alone did not inhibit in vivo tumor growth and did not enhance rapamycin-mediated growth inhibition. In conclusion, rapamycin causes significant growth inhibition in carcinoid tumor cell lines in vitro and in vivo, thus mTOR is a promising therapeutic target for neuroendocrine tumors. Octreotide does not enhance the efficacy of rapamycin's antiproliferative effects in the models tested, and does not inhibit rapamycin-mediated feedback activation of Akt. Further study is needed in order to determine whether octreotide or other somatostatin analogs enhance the efficacy of mTOR inhibitors in other models.

PubMed Disclaimer

Cited by

PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J. Meric-Bernstam F, et al. Clin Cancer Res. 2012 Mar 15;18(6):1777-89. doi: 10.1158/1078-0432.CCR-11-2123. Clin Cancer Res. 2012. PMID: 22422409 Free PMC article.
Igf-I influences everolimus activity in medullary thyroid carcinoma.
Gentilin E, Di Pasquale C, Rossi M, Tagliati F, Gagliano T, Rossi R, Pelizzo M, Merante Boschin I, Degli Uberti EC, Zatelli MC. Gentilin E, et al. Front Endocrinol (Lausanne). 2015 May 5;6:63. doi: 10.3389/fendo.2015.00063. eCollection 2015. Front Endocrinol (Lausanne). 2015. PMID: 25999915 Free PMC article.
Systemic treatment for lung carcinoids: from bench to bedside.
Torniai M, Scortichini L, Tronconi F, Rubini C, Morgese F, Rinaldi S, Mazzanti P, Berardi R. Torniai M, et al. Clin Transl Med. 2019 Jul 4;8(1):22. doi: 10.1186/s40169-019-0238-5. Clin Transl Med. 2019. PMID: 31273555 Free PMC article. Review.
Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors.
Kawaguchi Y, Maruno A, Kawashima Y, Ito H, Ogawa M, Mine T. Kawaguchi Y, et al. World J Gastroenterol. 2014 Nov 14;20(42):15920-4. doi: 10.3748/wjg.v20.i42.15920. World J Gastroenterol. 2014. PMID: 25400479 Free PMC article.
Novel classification based on immunohistochemistry combined with hierarchical clustering analysis in non-functioning neuroendocrine tumor patients.
Iida S, Miki Y, Ono K, Akahira J, Suzuki T, Ishida K, Watanabe M, Sasano H. Iida S, et al. Cancer Sci. 2010 Oct;101(10):2278-85. doi: 10.1111/j.1349-7006.2010.01657.x. Epub 2010 Aug 2. Cancer Sci. 2010. PMID: 20682006 Free PMC article.

Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors - PubMed (original) (raw)